LYMPHOMAS

Guess the Diagnosis

Guess the Diagnosis

Infusions of CTL019, a CAR-modified T-cell therapy against CD19, achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive DLBCL, MCL, and FL.

Treatment with the PD-1 inhibitor nivolumab demonstrated durable objective response rates in patients with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).

The 1.8-mg/kg dose of polatuzumab vedotin is as effective as the 2.4-mg/kg dose on the endpoint of progression-free survival in patients with relapsed/refractory non-Hodgkin lymphoma while improving tolerability, according to a pooled analysis of phase I and phase II clinical studies.

Treatment with obinutuzumab in combination with bendamustine nearly doubled progression-free survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

While ibrutinib is a relatively new option in the treatment of B-cell NHL, it has convincing antitumor activity as a single agent in a wide variety of B-cell lymphoma subtypes and is a viable therapeutic option for patients.

Common AEs associated with brentuximab vedotin, such as peripheral neuropathy and neutropenia, are often manageable with modifications to dose and schedule.

Duvelisib (IPI-145) is an orally administered, dual inhibitor of phosphoinositide 3-kinase (PI3K) delta (δ) and gamma (γ) isoforms, and the drug is selective for PI3K class I isoforms over other lipid and protein kinases.